BioWorld - Thursday, December 25, 2025

FDA
FDA RSS Feed RSS

FDA guidance roils Saniona’s stock

Oct. 9, 2020
By Lee Landenberger
The regulatory path for Saniona AB’s Tesomet for treating two rare eating disorders, Prader-Willi syndrome (PWS) and hypothalamic obesity, continues to be a winding one with surprises along the way. The newest twist is pre-IND feedback from the FDA that knocked the stock down 10.5% on Oct. 9.
Read More
Psychiatric disorders illustration

Slammin’ sami, FDA panels endorse Alkermes drug but provide no home run

Oct. 9, 2020
By Randy Osborne
Opioid-related hazards with Alkermes plc’s combo drug ALKS-3831 – specifically, with the samidorphan element – and the significance of weight-gain reduction brought about by the tablet, which also includes olanzapine, became key topics in the joint meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
Read More
Cybersecurity data lock
The Food and Drug Law Institute Annual Conference

FDA eyes 2021 for reissue of Oct. 2018 premarket cybersecurity draft guidance

Oct. 8, 2020
By Mark McCarty
There are some U.S. FDA work items that have been hampered primarily by the COVID-19 pandemic, and some that have just proven difficult to push across the finish line. The FDA’s October 2018 draft guidance for premarket considerations for cybersecurity in medical devices might fall into that latter category, but the FDA’s Suzanne Schwartz said the agency will reissue another draft version of that guidance, which will be available sometime in early 2021.
Read More
Microscope and coronavirus illustration

Stenzel says FDA will no longer review LDTs under EUA for COVID-19 pandemic

Oct. 7, 2020
By Mark McCarty
The U.S. FDA will no longer review lab-developed tests (LDTs) for the SARS-CoV-2 virus under the emergency use authorization (EUA) program, a change that will eliminate any prospect of immunity from liability for these tests. The FDA’s Tim Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health, announced the news on the weekly COVID-19 testing town hall, but the change was simultaneously unveiled in the FDA’s Q&A for testing.
Read More
Product image

FDA approves ablation catheter for treating persistent atrial fibrillation

Oct. 7, 2020
By David Godkin
Biosense Webster Inc. reported U.S. FDA approval of its Thermocool Smarttouch SF ablation catheter for the treatment of patients with persistent atrial fibrillation (persistent AF). This follows results of the prospective, multicenter Precept study, which showed the catheter to be safe and effective for 80% of patients over 15 months of ablation therapy with clinically meaningful improvement in quality of life.
Read More
Coronavirus and antibodies

Lilly seeks EUA for COVID-19 antibody treatment

Oct. 7, 2020
By Michael Fitzhugh
With an ongoing phase II trial showing that a pair of its SARS-CoV-2 neutralizing antibodies has so far reduced viral load, symptoms and COVID-19-related hospitalization and ER visits, Eli Lilly and Co. has asked the FDA to consider an emergency use authorization (EUA) for one of the components, LY-CoV555.
Read More

Vaccine guidance, adcom a matter of raising public trust

Oct. 7, 2020
By Mari Serebrov
With COVID-19 cases once again surging across the globe and several countries considering targeted lockdowns, vaccines remain the best hope of restoring a sense of normalcy amidst the pandemic. For vaccines to work though, people must have enough confidence in the efficacy and safety that they’re willing to get vaccinated when the vaccines become available. That’s why the emergency use authorization (EUA) guidance the FDA released Oct. 6 for COVID-19 vaccines is so important.
Read More